NV-KALRAY
Kalray (Euronext Growth Paris: ALKAL), a technology innovator building software and hardware solutions that accelerate data-intensive workflows, announced Ngenea® for AI, a new edition of its Kalray Data Acceleration Platform specifically fine-tuned for AI data pipelines. As AI demands new ways to ingest and access massive volumes of data, Ngenea for AI helps teams speed up performance, simplify data management and open their data assets to new AI-powered use cases.
Ngenea for AI is the companion to two Ngenea editions for Media & Entertainment and HPC customers, respectively. The new Ngenea for AI empowers AI innovators to speed up their ingest performance and access their unstructured data from a unified, global name space. Kalray debuted Ngenea for AI at Dell Technologies World 2024 in Las Vegas today, where the software’s performance on Dell servers is being showcased in the Kalray Booth #1026.
The generative AI (GenAI) market is predicted to see 42% compound annual growth rate (CAGR) across the next 10 years into a $1.3 trillion space, from just $40 billion in 2022 (Bloomberg Intelligence). Yet innovative AI constructs such as large language models (LLMs) and Retrieval-Augmented Generation (RAG), and applications including Smart Vision and GenAI, are challenging the ability of IT systems to move data to and from their massive data stores.
ENABLING GENAI AND RAG
Ngenea for AI adds data indexing and search capabilities, which users can leverage to feed any data to Smart Vision, GenAI and RAG applications effortlessly. The new offering enables AI customers to fully harness their existing assets when deploying GenAI applications, regardless of where the data is stored. These GenAI and RAG capabilities simplify and automate what would otherwise be a complex workflow from a data management aspect.
”Fast AI processing is mission-critical to our business of detecting railcar anomalies before they lead to breakdowns or derailments. With Ngenea deployed along with Dell Technologies products, Duos achieved a 120x performance boost on our Railcar Inspection Portal (RIP®) solution, and an 8x increase in inspection accuracy. Working with Kalray helped us put railroads at the forefront of innovation,” said Jeff Necciai, chief technology officer of Duos Technologies.
HIGH-PERFORMANCE STORAGE TIER TO FEED GPUS EFFORTLESSLY
The Ngenea for AI platform also incorporates a high-performance storage tier for the most data-intensive AI workloads. The tier is powered by a proven high-performance parallel file system that can easily manage petabytes of data and billions of files – whether data live on the edge, in the cloud, or on premises. This allows customers and partners to maximize the value of their GPU investment, without rip-and-replace deployments.
With Ngenea, AI innovators:
- Accelerate AI workflows by optimizing AI data pipelines and enhancing the overall speed and efficiency of AI operations.
- Boost the AI model performance by feeding data to GPUs faster, allowing for quicker computations and accelerated insights.
- Gain advanced data indexing capabilities that enable Generative AI and RAG applications to deliver more refined search functionalities, enabling more effective queries and a more strategic utilization of AI models.
- Facilitate a controlled and optimized connection between company data and a suite of third-party AI-powered tools, ensuring seamless integration and data synergy.
Optional hardware acceleration via Kalray’s DPUs including the TURBOCARD4 (TC4) allows parallel processing in an asynchronous way for ultra-demanding workflows, via a complementary architecture to GPUs.
“Even with the tremendous commitment that C-suite leaders are making to AI, very few CIOs have the sizable budgets required to deploy a new system solely for an AI rollout,” said Scott Sinclair, practice director, infrastructure, and modernization, at the Enterprise Strategy Group TM. “Innovative use cases that enable enterprises to leverage their existing infrastructure and still deploy novel AI applications address a sizable untapped need in the market.”
AI TOOLKIT FOR EASY INTEGRATION
Ngenea for AI includes an AI Toolkit that Kalray partners can use for easy integration of their applications with Ngenea. For example, when integrating Ngenea with Perifery Vision AI, users can intuitively search for historical content across a vast amount of data on locations, types, and collections.
“Traditional data centers weren’t built for massive data sets found in AI workloads – or to process these workloads rapidly and efficiently,“ said Eric Baissus, CEO of Kalray. “Kalray’s Ngenea for AI is the data acceleration platform for the AI age – software that elevates performance on existing servers and storage and provides toolkits that streamline application integration. With our software, enterprises and service providers can feed GPUs effortlessly - optimizing data movement and orchestration as the foundation of their infrastructure - so that AI genuinely delivers a competitive edge.“
The Ngenea for AI platform joins two other Ngenea editions that streamline application integration for specific use cases: Ngenea for HPC – providing scratch storage, or storage for temporary user data, and Ngenea for Media & Entertainment – to accelerate post-production workflows.
Ngenea for AI is available today from Dell, from Kalray and select partners. For more information visit here.
ABOUT KALRAY
Kalray is a technology innovator specializing in software and hardware solutions to accelerate data-intensive workflows in Media & Entertainment, High-Performance Computing, and Artificial Intelligence. Our comprehensive product range features Ngenea, a leading data acceleration platform, as well as accelerated data processing cards for storage and compute.
With Kalray solutions, customers can scale their infrastructures to efficiently meet the performance and capacity needs of data-intensive tasks, all without being tied to specific data formats or vendors.
Founded in 2008 as a spin-off from the French CEA research lab, Kalray has corporate and financial backing from notable investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors, and Bpifrance. Committed to innovation and excellence, we strive to deliver value to our customers, developers, and the planet through technology and expertise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521509685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom